UNSPSC 51172905: Dutasteride/tamsulosin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GU900. This VA Drug Class (GU900) classifies this compound as belonging to the group GENITO-URINARY AGENTS, OTHER.

UNSPSC 51172905 Dutasteride/tamsulosin (Commodity) shows a mismatch between its nominal scope—a pharmaceutical product for benign prostatic hyperplasia—and recent state and local procurement activity. The three most recent opportunities tagged under this code involve industrial valve parts and repair services for wastewater treatment, parenteral nutrition and intravenous solutions for correctional healthcare, and sodium bisulfite chemical supply for water treatment operations. None of these commodities align with the code's stated pharmaceutical product. State and local procurement offices appear to be using this code inconsistently or incorrectly for water and health system procurement that falls outside dutasteride/tamsulosin's therapeutic scope.

The recent opportunities span Washington State (Department of Corrections, RFQ for parenteral products and equipment, due October 7, 2026), Florida (Broward County, RFI for DeZurik/APCO valve parts and repair services, due September 29, 2026), and Connecticut (City of Meriden, IFB for sodium bisulfite, due July 29, 2026). Issuing bodies include state corrections agencies, county water and wastewater authorities, and municipal utilities. Given the commodity mismatch across all three opportunities, this code shows little relevant recent activity for firms pursuing state and local contracts in pharmaceutical supply or distribution.